Fig. 2
From: KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
MRTX1257 increases the efficacy of RT in nude mice bearing CT26 KRASG12C+/+ however without achieving durable responses A Athymic nude mice were subcutaneously inoculated with CT26 KRASG12C+/+ cells. Once the tumors reached an average volume of 90–100 mm3, mice received via oral administration 50 mg/kg of MRTX1257 or vehicle. The day after, mice received a single fraction of 6 Gy on the tumor mass. MRTX1257 at the dose of 50 mg/kg or vehicle were then administered at D1 and D3 after RT. The experiment was repeated twice. B Tumor growth (mean ± SEM) ***: p < 0.001; ****: p < 0.0001 (two-way ANOVA). C Mean tumor volumes in each group 10 days after RT are represented. *: p < 0.05; ***: p < 0.001; ****: p < 0.0001 (one-way ANOVA). D Individual growth profiles of CT26 KRAS.G12C+/+ tumors are represented for each condition. E Survival Kaplan–Meier curves were compared between each group using the log-rank test. **: p < 0.01; ****: p < 0.0001